Skin Diseases Associated with Biologic Therapies

  • Sharon Rose
  • Shivani B. Kaushik
  • Mark Lebwohl


Biologics have become the mainstay of many dermatological and systemic diseases in our current practice. While safety and efficacy of these drugs has been proven extensively in clinical trials, these drugs possess the potential for cutaneous as well as systemic toxicity owing to their immunosuppressive effects. This book chapter focuses on the adverse cutaneous reactions observed with biologics, specifically tumor necrosis factor-alpha inhibitors. These side effects can include but are not limited to injection site reactions, hypersensitivity reactions, psoriasiform eruptions, eczema, vasculitis, and lupus-like reactions.


Biologics TNF-alpha Skin reaction Psoriasis 


  1. 1.
    Wlodarczyk M, Sobolewska A, Wojcik B, Loga K, Fichna J, Wisniewska-Jarosinska M. Correlations between skin lesions induced by anti-tumor necrosis factor-alpha and selected cytokines in Crohn's disease patients. World J Gastroenterol. 2014;20(22):7019–26.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Kashat M, Caretti K, Kado J. Etanercept-induced cystic acne. Cutis. 2014;94(1):31–2.PubMedGoogle Scholar
  3. 3.
    Nagy G, Lukacs K, Sziray A, Fazekas K, Florian A, Tamasi L, et al. [Adverse events during biological therapy—focusing on dermatological side-effects]. Orv Hetil. 2011;152(6):212–20.Google Scholar
  4. 4.
    Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32–8.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486–504.CrossRefPubMedGoogle Scholar
  6. 6.
    Hernandez MV, Meineri M, Sanmarti R. Skin lesions and treatment with tumor necrosis factor alpha antagonists. Reumatol Clin. 2013;9(1):53–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008;66(5):618–25.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Lobel EZ, Korelitz BI, Warman JI. Red man syndrome and infliximab. J Clin Gastroenterol. 2003;36(2):186.CrossRefPubMedGoogle Scholar
  9. 9.
    Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004;10(4):333–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Puig L. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients]. Actas dermo-sifiliograficas. 2008;99(Suppl 4):30–5.Google Scholar
  12. 12.
    Keystone E, Heijde D, Mason D Jr, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319–29.CrossRefPubMedGoogle Scholar
  13. 13.
    Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789–96.CrossRefPubMedGoogle Scholar
  14. 14.
    Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, Blanco R, Fernandez-Llaca H, Rodriguez-Valverde V, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007;32(6):672–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137(7):893–9.PubMedGoogle Scholar
  16. 16.
    Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301(1):99–105.CrossRefPubMedGoogle Scholar
  19. 19.
    De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545–51.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14(12):931–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005;1051:559–69.CrossRefPubMedGoogle Scholar
  22. 22.
    Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43(11):2383–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64(3):403–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535–43.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52(7):2192–201.CrossRefPubMedGoogle Scholar
  27. 27.
    Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31(10):1912–7.PubMedGoogle Scholar
  28. 28.
    Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50(5):619–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37(6):381–7.CrossRefPubMedGoogle Scholar
  30. 30.
    D’Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004;255(3):409–18.CrossRefPubMedGoogle Scholar
  31. 31.
    Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001;167(12):6821–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102(9):3372–7.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol. 2014;170(2):366–73.CrossRefPubMedGoogle Scholar
  34. 34.
    Bernardo S, Geraghty L, Frelich A, Pan M, Lebwohl M. Frequency of monotherapy versus combination therapy in reported cases of infections occurring in the setting of biologic agents. Psoriasis Forum. 2013;19(1).Google Scholar
  35. 35.
    Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti- TNF therapy and increased risk of infections. Drug, Healthc Patient Saf. 2013;5:79–99.CrossRefGoogle Scholar
  36. 36.
    Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67(2):245–56.CrossRefPubMedGoogle Scholar
  37. 37.
    Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(3):215–21.CrossRefPubMedGoogle Scholar
  38. 38.
    Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26(9):1127–32.CrossRefPubMedGoogle Scholar
  39. 39.
    Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28(7):846–52.CrossRefPubMedGoogle Scholar
  40. 40.
    van Lumig PP, Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol. 2012;26(3):283–91.CrossRefPubMedGoogle Scholar
  41. 41.
    Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–17.CrossRefPubMedGoogle Scholar
  42. 42.
    Hooper M, Wenkert D, Bitman B, Dias VC, Bartley Y. Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatr Rheumatol Online J. 2013;11(1):35.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Bachmeyer C, Thioliere B, Khosrotehrani K, Cattan E. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol. 2007;56(1):169–70.CrossRefPubMedGoogle Scholar
  44. 44.
    Meyboom RH, Star K, Bate J, Savage R, Edwards IR. TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf. 2008;31(5):445–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 2010;33(10):865–78.CrossRefPubMedGoogle Scholar
  46. 46.
    Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146(4):941–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Raaschou P, Simard JF, Holmqvist M, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939.CrossRefPubMedGoogle Scholar
  48. 48.
    Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012;42(3):223–33.CrossRefPubMedGoogle Scholar
  49. 49.
    Lee MS, Lin RY, Chang YT, Lai MS. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int J Dermatol. 2012;51(12):1454–60.CrossRefPubMedGoogle Scholar
  50. 50.
    Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39(5):481–92.CrossRefPubMedGoogle Scholar
  51. 51.
    Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68(2):209–15.CrossRefPubMedGoogle Scholar
  52. 52.
    Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52(8):2513–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156(3):486–91.CrossRefPubMedGoogle Scholar
  54. 54.
    Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–76.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Mocciaro F, Renna S, Orlando A, Cottone M. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol. 2009;104(11):2867–8.CrossRefPubMedGoogle Scholar
  56. 56.
    Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol. 2010;146(9):1055–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol. 2007;143(2):233–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7(7):517–24.CrossRefPubMedGoogle Scholar
  59. 59.
    Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40.CrossRefPubMedGoogle Scholar
  60. 60.
    Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–85.CrossRefPubMedGoogle Scholar
  61. 61.
    Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100–8.CrossRefPubMedGoogle Scholar
  62. 62.
    de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223–31.CrossRefPubMedGoogle Scholar
  63. 63.
    Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol. 2005;153(6):1243–4.CrossRefPubMedGoogle Scholar
  64. 64.
    Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–77.CrossRefPubMedGoogle Scholar
  65. 65.
    Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005;44(2):172–5.CrossRefGoogle Scholar
  67. 67.
    Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001;81(3):335–47.CrossRefPubMedGoogle Scholar
  68. 68.
    Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31(10):1955–8.PubMedGoogle Scholar
  69. 69.
    Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Modern Rheumatol. 2010;20(1):86–9.CrossRefGoogle Scholar
  70. 70.
    Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis and rheumatism. 2006;55(5):817–20.Google Scholar
  71. 71.
    Bremner R, Simpson E, White CR, Morrison L, Deodhar A. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum. 2004;34(3):610–6.CrossRefPubMedGoogle Scholar
  72. 72.
    Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142(2):198–202.CrossRefPubMedGoogle Scholar
  73. 73.
    Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):567–70.CrossRefPubMedGoogle Scholar
  74. 74.
    Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61(1):104–11.CrossRefPubMedGoogle Scholar
  75. 75.
    Garcovich S, Burlando M, Rongioletti F, Garcovich A, Parodi A, Amerio P. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect. Acta Derm Venereol. 2010;90(3):311–2.CrossRefPubMedGoogle Scholar
  76. 76.
    Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–78.CrossRefPubMedGoogle Scholar
  77. 77.
    Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29(5):563–6.CrossRefPubMedGoogle Scholar
  78. 78.
    Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22(7):1300–3.PubMedGoogle Scholar
  79. 79.
    Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int. 2013;33(4):965–71.CrossRefPubMedGoogle Scholar
  80. 80.
    So MW, Koo BS, Kim YG, Lee CK, Yoo B. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol. 2011;38(11):2432–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;14(4):291–313.CrossRefPubMedGoogle Scholar
  83. 83.
    Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol. 1982;6(2):253–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica. 1990;180(4):212–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sharon Rose
    • 1
  • Shivani B. Kaushik
    • 1
  • Mark Lebwohl
    • 1
  1. 1.Department of DermatologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations